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naczyń (zespołu Churga-Strauss)
The authors declare no finacial disclosure
Abstract 
Patients with cardiovascular symptoms are mainly diagnosed in cardiological wards. However, sometimes the other reasons 
for acute coronary syndrome and heart failure are found. One of such reasons is hypereosinophilia which can be recognized if 
number of blood eosinophils exceeds 1500/mm3. High eosinophilia is connected with production of cytotoxic eosinophilic proteins 
which can cause eosinophilic vasculitis or eosinophilic myocarditis. One of the better known hypereosinophilic syndromes is 
EGPA described by the pathomorphologists Churg and Strauss. The further research works allowed for the clinical characteristics 
of patients with EGPA. In the course of this disease the following three phases were recognized : prodromal-allergic, eosinophi-
lic, vasculitic. The definitive diagnosis can be established only in the third phase, when vasculitis causes organ involvement. 
Besides symptoms of the respiratory tract (asthma, nasal polyps, eosinophilic lung infiltrations) also cardiovascular symptoms, 
gastrointestinal tract symptoms, as well as skin lesions and kidneys involvement can appear. The most dangerous for patients is 
involvement of the nervous and cardiovascular systems. We present a patient with asthma and eosinophilia in whom EGPA was 
diagnosed in the course of acute recurrent substernal chest pain, with subsequent signs of cardiac insufficiency.
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Streszczenie
Chorzy z objawami ze strony układu krążenia są diagnozowani przede wszystkim w oddziałach kardiologii. Czasem jednak objawy 
o typie ostrego zespołu wieńcowego czy ostrej niewydolności serca są spowodowane innymi przyczynami. Jedną z nich jest hype-
reozynofilia tzn., stan gdy liczba eozynofilów przekracza 1500/mm3. Zwiększona liczba eozynofilów oraz nadmierna produkcja przez 
nie cytotoksycznych białek mogą wywołać m.in. kwasochłonne zapalenie naczyń czy kwasochłonne zapalenie serca. Jednym 
z lepiej poznanych zespołów samoistnej hypereozynofilii jest EGPA (eosinophilic granulomatosis with polyangiitis) opisane przez 
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Churga i Strauss i scharakteryzowane przez nich cechami patomorfologicznymi. Dalsze badania pozwoliły na określenie przebiegu 
klinicznego EGPA. Wyróżniono 3 następujące fazy: prodromalną związaną z objawami alergii, fazę eozynofilii obwodowej i tkanko-
wej oraz fazę zapalenia naczyń. Rozpoznanie ostateczne można ustalić dopiero w fazie 3, gdy wystąpi zapalenie naczyń i wywoła 
objawy narządowe. Obok objawów ze strony układu oddechowego ( astma, polipy nosa, nacieki kwasochłonne w płucach) mogą 
wystąpić objawy ze strony układu krążenia, pokarmowego, skóry, nerek. Najniebezpieczniejszymi są objawy ze strony układu 
nerwowego i układu krążenia. Opisujemy chorego z astmą i eozynofilią, u którego dopiero wystąpienie ostrego bólu dławicowego 
z objawami niewydolności serca doprowadziło do rozpoznania EGPA
Słowa kluczowe: eozynoflilia, obrzęk płuc, eozynofilowe zapalenie mięśnia serca, EGPA
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Introduction
Patients with substernal pain and signs of 
cardiac insufficiency are usually hospitalized 
in the cardiac intensive care unit. High levels of 
necrotic markers without occluded arteries at cor-
onarography suggest other reasons for the acute 
coronary syndrome. One of those reasons can be 
eosinophilic coronary vasculitis and eosinophilic 
myocarditis in the course of eosinophilic gran-
ulomatosis with polyangiitis (EGPA), formerly 
Churg-Strauss syndrome [1−3].
We present a patient with EGPA diagnosed 
after the appearance of heart symptoms.
Case report
A 55-year-old man, nonsmoker, with the his-
tory of nasal polyps , after polypectomy in 2012, 
with asthma and mild eosinophilia, was admitted 
in January 2014 to the IIIrd Department of Lung 
Diseases in the National Institute of Tuberculosis 
and Lung Diseases because of the massive lung 
lesions found in radiological examination.
Symptoms had begun on the 15 of December 
2013 with abrupt onset of severe and reccurrent 
substernal chest pains, the longest lasting for 
20 minutes, with acute dyspnea, severe cough 
and hemoptysis especially in the supine position 
and after exertion.
He was hospitalized with suspicion of heart 
infarct in the Clinic of Cardiology , then in the 
Clinic of Internal Diseases. WBC was from 16.53 
× 109 /mm 3 to 20.16 × 109/mm3 and eosinophilia 
from 7.11 × 109/mm 3 to 7.68 × 109/mm3, 43% to 
38.1%, respectively. D-dimer, other biochemical 
parameters were within normal limits. In electro-
cardiogram (ECG) ST segment elevation in precor-
dial leads was observed, with poor anteroseptal 
R-wave progression , and diffuse T-wave inversion 
(Fig. 1). High level of troponin up to 21.727 ng/ 
/ml (normal result < 0.1 ng/ml) and CK-MB up 
to 104.1 IU/l (normal limits 2−24 IU/l) suggested 
heart muscle necrosis.
A diagnosis of myocardial infarct was sus-
pected. Echocardiography showed decreased 
contractility of the left ventricle (LV), LV ejection 
fraction (LVEF) was 35%, and very small amount 
Figure 1. Electrocardiogram (ECG): ST segment elevation in precordial leads with poor anteroseptal R-wave progression, and T-wave inversion
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of fluid in pericardium was present. Coronarog-
raphy revealed only segmental small discentric 
atheroslerosis up to 40−50% of the lumen in left 
anterior descending artery (LAD). Then heart infarct 
was excluded and acute coronary syndrome with 
suspicion of cardiomyopathy in the patient with 
asthma and nasal polyps was diagnosed. A few days 
later the patient’s performance status worsened.
Chest-x ray and CT scans were done due to 
suspicion of interstitial lung disease, and revealed 
the presence of parenchymal consolidations and 
ground glass shadows. The patient was treated 
with several antibiotics because of suspicion of 
pneumonia, also with inhaled corticosteroids 
and bronchodilatators, furosemidum, nebivolol, 
and etamsylat. He still complained for shortness 
of breath, so in January 2014 he received hy-
drocortisone hemisuccinatum intravenously for 
a few days. After this therapy he felt better and 
was send to the National Institute of Tuberculosis 
and Lung Diseases for diagnosis and treatment of 
lung lesions.
Previous history: Two years earlier, in 2011, 
the diagnosis of asthma and nasal polyps was 
established. He was treated with inhaled bron-
chodilator and inhaled corticosteroid with clin-
ical improvement. In January 2013 chest x-ray 
revealed slightly enlarged hilar lymph nodes (Fig. 
2). On high resolution computed tomography of 
lungs (HRCT), delicate disseminated lesions in 
the middle and lower parts of lungs with slight 
enlargement of hilar lymph nodes were found. 
Radiologic appearance could be connected with 
sarcoidosis but histologic examination of the 
bronchial wall samples taken during bronchofi-
beroscopy did not confirm sarcoidosis, signs of 
chronic inflammation with some eosinophilis 
were seen. WBC was from 7.71 × 109/mm3 to 
7.88 × 109/mm3, eosinophils from 0.99 to 1.2 
× 109/mm3, from 14.3% to 15.6%, respectively. 
In spirometry mild obstruction with significant 
increase of FEV1 and FVC after salbutamol was 
observed. After discharge from the hospital he 
continued treatment with inhaled bronchodilator, 
inhaled and nasal corticosteroid. His GP advised 
him to start therapy with leukotriene receptor 
antagonist (montelukast) and patient had been 
treated with this drug for a few months.
In January 2014 the patient was admitted to 
the National Institute of Tuberculosis and Lung 
Disease. He was in a severe state, he had short-
ness of breath at rest, especially when lying in 
bed, and after slight exertion, with severe cough, 
hemoptysis, and substernal pain. Physical exam-
inations were unremarkable. He had no symptoms 
of viral or bacterial infection. Blood examination 
tests revealed WBC 12.7 × 109 /mm3, with high 
eosinophilia 30.6%, 3.88 × 109 /mm3. IgE level 
was slightly elevated to 125.8 IU/ml (normal 
limits 0−100.0 IU/ml). ANCA (antineutrophil 
cytoplasmic antibodies) test was negative. CRP 
77.9 mg/l (normal result < 10). Troponin level 
was 0.25 ng/ml. Pro-BNP was elevated to 4702 
pg/ml (normal limits 0–125 pg/ml).
Arterialized blood gases revealed hypoxemia, 
PaO2 was 55.6 mm Hg, Sat.O2 91.4%, PaCO2 35 
mm Hg, pH 7.48, HCO3 26 mmol/l. Initially he 
was treated with oxygen, nebivol and additionally 
with diuretics. Some short lasting relief of symp-
toms was observed. Neurologic examination did 
Figure 2. Initial chest X-ray — both lungs and heart are normal; 
slightly enlarged hila
Figure 3. Chest X-ray after one year — big, perihilar foci of abnormal 
opacities, bilateral pleural effusion; heart is slightly enlarged
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not reveal any pathologic signs. The result of the 
radiologist’s consultation of the chest X-ray and 
CT scans done in the Cardiological Ward, was as 
follows: massive parenchymal lesions caused by 
lung edema in the course of the left ventricular 
heart insufficiency with bilateral pleural fluid 
(Figs 3, 4AB). In ECG ST segment depression, 
poor R wave progression in precordial leads, and 
diffuse T-wave inversion were observed.
Echocardiography revealed severe hypokine-
sis of the left ventricular wall, LVEF was very low, 
29%, also small amount of pericardial effusion 
was seen.
Magnetic resonance of the heart (CMR) re-
vealed signs of acute myocarditis, indicative of 
eosinophilic etiology. Prominent delayed contrast 
enhancement (DE) in endocardium of the left 
ventricle (LV) was observed, mostly prominent 
in the apical, and basal segments. Additionally, 
subepicardial, intramural as well as right ventric-
le (RV) involvement was present.
T2-weighted images revealed increased si-
gnal of LV myocardium as compared to the 
skeletal muscles, indicative of myocardial edema. 
Subendocardial perfusion defects were observed 
in the apical and basal segments of the left ven-
tricle. LVEF was low, 36% (Figs 5−8).
The above mentioned cardiac disturbances 
in patient with asthma, nasal polyps, high eosi-
nophilia > 1500/mm3, were diagnosed as EGPA 
with eosinophilic myocarditis and cardiac failure.
Our patient started treatment with pred-
nisone 1 mg/kg per day (60 mg) and cyclopho-
sphamide 2 mg/kg per day (150 mg). Clinical 
improvement was observed very soon. Control 
examination of blood after 1 week of therapy 
Figure 4. A — CT, mediastinal window: big amount of pleural fluid bilaterally; B — CT, lung window: bilateral, perihilar foci of ground-glass opacity 
and thickened interlobular septa
A B
Figure 5. Cine images in four chamber view: end-systole (left), end-diastole (right). Impairment of systolic LV function. LVEF reduced to 36%. Small 
pericardial effusion
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Figure 6. Increased T2 signal ratio between myocardium and sceletal muscles > 2 , suggestive of acute myocarditis
Figure 7. First-pass perfusion, short axis view at basal level. Subendocardial 
perfusion deficits (arrows) pronounced in the lateral segments (thick arrows)
Figure 8. DE image in four chamber view shows typical for eosinophi-
lic myocarditis enhancement pattern involving endocardium, epicar-
dium and intramural myocardium. Black arrows: subendocardial DE, 
white arrows: epicardial and intramural DE, grey arrows: intramural 
and RV subendocardial DE in the interventricular septumrevealed no eosinophilia and normalization of 
troponin level. One month later patient was in a 
good condition with better tolerance of exertion. 
At echocardiography partial remission was ob-
served, EF increased to 41%. Chest x-ray revealed 
regression of the previous lesions (Fig. 9). Patient 
continued immunosuppressive treatment, and he 
was allowed to return to work.
Disscusion
EGPA is a rare disease, very difficult to 
diagnose. The clinical course of EGPA is charac-
terized by the three phases such as: 1. allergic 
inflammation of the upper airways with polyps, 
asthma, often corticosteroid-dependent 2. blo-
od and tissue eosinophilia without vasculitis 
3. organ involvement caused by eosinophilic 
and necrotizing vasculitis [4]. In some patients 
the above mentioned phases can appear simul-
taneously. Rarely the upper airways allergy is 
not evident until the development of vasculitis 
[5−7]. In our patient allergic inflammation of the 
upper airways with nasal polyps, and asthma 
have been diagnosed at the same time two years 
before the heart involvement. Mild blood eosino-
philia and eosinophils in histologic examination 
from bronchial wall were found 1 year before the 
EGPA diagnosis.
Although, those phases of EGPA are known, 
the diagnosis of this disease can be established 
Jolanta Załęska et al., Severe congestive heart failure in EGPA
587www.pneumonologia.viamedica.pl
only in the third phase when the organ involve-
ment appears. In the case with high eosinophilia 
and suspicion of myocardial or coronary arteries 
involvement, histologic confirmation of EGPA is 
often impossible to achieve. In those cases diagno-
sis have to be established based on the following 
criteria defined by Guillevin et al. from the French 
Vasculitis Group: asthma, eosinophilia > 1500/mm3 
or > 10% of WBC, clinical manifestation consistent 
with systemic vasculitis, with or without histolo-
gic evidence [1, 5]. Our patient had nasal polyps, 
asthma, high blood eosinophilia, and eosinophilic 
myocarditis (EM) with congestive heart failure, so 
according to the above diagnostic criteria descri-
bed by members of the French Vasculitis Group 
we established the diagnosis of EGPA.
In the pathogenesis of EGPA a major role play 
eosinophils. Activated tissue eosinophils release 
toxic granule proteins such as eosinophil basic 
protein (EBP), eosinophil cationic protein (ECP), 
eosinophil peroxidase (EP), eosinophil – derived 
neurotoxin (EDN), which can damage surroun-
ding tissue. Especially ECP and EBP are known 
as the tissue-damaging protein. Activity of these 
two cytotoxic proteins is very dangerous for heart 
and neurologic system [2, 8, 9].The number of 
eosinophils increases rapidly in the 2nd and 3rd 
phase of disease.
There are three following stages of heart 
damage caused by eosinophilic proteins: 1. acute 
myocardial necrosis, characterized by eosinophil 
damage of endocardium and infiltration of my-
ocardium mainly with eosinophils, in histologic 
examination myocardial necrosis with eosinophil 
microabsceses is seen, 2. thrombotic stage, cha-
racterized by formation of thrombi along the en-
Figure 9. Follow-up chest X-ray after treatment is normal
docardium, fibrosis of endocardium, myocardium, 
and chordae tendinae, leading to endomyocardial 
fibrosis complicated by restrictive cardiomyopa-
thy, and 3.valve dysfunctions [2, 5, 8, 10, 11].
Cardiac involvement in EGPA can be ob-
served in about 27−60% of patients.
Cardiac manifestations can vary from mild 
symptoms to the life-threatening entities [3, 9, 12]. 
According to the reports of Guillevin et al. car-
diac involvement in EGPA can even range from 
16.6% of patients, when assessed by electrocar-
diography, to 92.3% of patients, when assessed 
by the postmortem examination [1]. Cardiac 
insufficiency was estimated as 34% of patients 
with EGPA, and was connected with increased 
mortality rate. Among patients with heart failure/ 
cardiomyopathy caused by EGPA the mortality 
rate was estimated as up to 50% [1, 6, 11].
In EGPA patients cardiac involvement may 
be demonstrated clinically as: acute pericarditis, 
pericardial eosinophilic effusion, myocarditis, 
endocarditis, endomyocarditis, myocardial isch-
emia, arrhythmia, conductance disturbances, 
coronary vasculitis, valvular heart dysfunction, 
sudden cardiac death. Complications of the above 
mentioned cardiac disease in EGPA can be as 
follows: contrictive pericarditis , acute left ven-
tricular dysfunction , cardiomyopathy, congestive 
heart failure, myocardial fibrosis, intracavitary 
thrombus, cardiac tamponade [3, 6, 10, 13−16].
Acute and constrictive pericarditis (8−35%), 
eosinophilic myocarditis (13−25%), heart failure 
(17%), signs of myocardial ischemia, coronary 
vasculitis, and arrhythmia were found in the 
majority of patients with heart involvement in 
EGPA [10, 15]. Neuman et al. published results 
of the analysis of 49 patients with EGPA, of those 
22 patients (45%) had cardiac disease, and in 13 of 
those — endomyocarditis was the major presen-
tation proved by CMR or histologic examination 
of the endomyocardial biopsy [2, 14].
The patient presented in this report had no 
preexistent heart disease. During hospitalization in 
the cardiology ward high troponin (21.727 ng/ml) 
and CK-MB levels (104 ng/ml) were found indi-
cating cardiac necrotic lesions, and electrocar-
diogram showed signs of heart ischemia. At this 
time also high blood eosinophilia was present 
but in the beginning it was not considered as an 
important finding. At echocardiography, diffuse 
hypokinesis with LVEF decreased to 35% was 
observed. Heart stroke was suspected initially 
but coronarography revealed only small dyscen-
tric atherosclerosis in LAD, so the diagnosis was 
changed to the suspicion of cardiomyopathy.
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The appearance of the new massive pulmo-
nary lesions was recognized by cardiologists as 
pneumonia. The accurate radiological estimation 
of pulmonary lesions as lung edema, in connec-
tion with asthma, and eosinophilia suggested 
EGPA. The presented patient had severe eosin-
ophilic myocarditis with heart failure, at echo-
cardiography acute left ventricular dysfunction 
with hypokinesis, and LVEF reduced to 29% was 
shown. In this phase of disease high blood eosin-
ophilia was also found.
Cardiac involvement in our patient with 
clinical suspicion of eosinophilic myocarditis 
was proved by cardiovascular magnetic res-
onance imaging (CMR) [17, 18]. CMR might 
serve as a noninvasive method for diagnosis of 
myocarditis. Delayed contrast enhancement, 
especially in apical and middle segments of LV 
is connected with active myocarditis in EGPA 
[18]. Our patient had similar pattern of lesions 
and radiologist conclusion was that examination 
indicated EM probably in EGPA. Moosig et al. 
reported that use of CMR increases the frequency 
of detecting heart involvement in the course of 
EGPA[19]. It is useful method in differentiating 
EGPA myocarditis from other causes of myocar-
dial diseases [17].
Even in patients with EGPA in remission, 
heart lesions in CMR can be found. Dennert et 
al. demonstrated, that in 62% of a group of 32 
patients with EGPA remission, CMR revealed 
cardiac involvement, such as wall motion distur-
bances then focal fibrosis, and in some patients 
obliterated RV, reduced LV function, and valvu-
lar disease. In the majority of those patients the 
subclinical heart disease was observed. Only 26% 
of examined patients (8 patients) complained of 
cardiac symptoms such as dyspnea, palpitations, 
and chest pain [6]. It is concluded that the deci-
sion to intesify treatment of patients with EGPA in 
remission with subclinical cardiac involvement 
is uncertain [6, 18].
Some authors pointed out that repeated un-
specific immunologic stimulation such as vacci-
nation, desensitization or quick discontinuation 
of systemic corticosteroid therapy in patients 
with unstable asthma could result in systemic 
vasculitis [1]. Our patient has been treated for 
a few months with leukotriene receptor antagonist 
(LRA). Wechsler et al. reported that in patients 
with uncontrolled moderate or severe asthma 
treated with systemic or even with high doses 
of inhaled corticosteroids and LRA, tapering 
the corticosteroids doses can be connected with 
unmasking of the underlying systemic vasculitis. 
However according to research works there is no 
evidence that LRA can directly cause vasculitic 
syndrome [20, 21].
Sable-Fourtassou et al. from the French Vas-
culitis Group analyzed the published patients 
with EGPA receiving LRA and found out that in 
the majority of them cardiomyopathy was diag-
nosed [22].
ANCA test in our patient with EGPA and 
congestive heart failure was negative. Two phe-
notypes of EGPA according to presence of ANCA 
are recognized , with clinical and pathogenetic 
differences. In about 40% of EGPA patients, 
ANCAs were found in examination of blood, 
and in the majority of cases these antibodies 
were myeloperoxidase (MPO)-specific ANCA. 
ANCA-positive EGPA is characterized by higher 
percentage of involvement of kidney, skin, periph-
eral nerves. On the contrary to that, most patients 
with ANCA-negative EGPA have higher involve-
ment of lungs and heart [1, 2, 5, 11, 17, 22]. 
Patients treated with antileukotriene drugs are 
usually ANCA-negative as our patient [20, 22]. 
More relapses, but better overall prognosis were de-
scribed in ANCA- positive EGPA [1, 2, 5, 11, 17, 22].
Patient with cardiac failure in the course of 
EGPA requires immediate immunosuppressive 
treatment with corticosteroid and cyclophospha-
mide, which can reduce the mortality rate and can 
improve myocardial function [1, 17, 19].
The prognosis in treated patients is good, re-
lapses were rarely observed. According to Guil-
levin et al. 10-year survival was achieved in above 
80% to 90% of patients [1]. However in some 
patients with heart involvement in the course of 
EGPA the prognosis was worse. Guillevin et al. 
reported that in the group of 96 patients, 
8 of them did not respond to immunosuppres-
sive treatment and died. During the follow-up 
32 patients died, among those — 5 patients be-
cause of the progressive cardiac insufficiency, 
4 — because of sudden death, probably due 
to heart insufficiency, the others died mainly 
because of the uncontrolled vasculitis [1]. Co-
marmond et al. after analysis of the clinical char-
acteristics and follow-up of 383 patients with 
EGPA concluded that cardiomyopathy is the 
main independent risk factor for death [17]. Our 
patient received treatment comprised of predni-
sone 1 mg/kg per day and of cyclophosphamide 
2 mg/kg per day orally. He responded very well 
to the immunosupressive therapy. After a few 
days eosinophilia disappeared and very soon 
clinical and the heart function improvement 
was observed.
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Conclusions
Patient with asthma, high eosinophilia and 
acute coronary syndrome without other causes 
should be suspected of the EGPA diagnosis. 
However, in this case always cardiological ex-
aminations, and especially coronarography are 
necessary to exclude heart disease. Nowadays 
cardiovascular magnetic resonance imaging might 
serve as a noninvasive method for the quick 
diagnosis of heart involvement. Among patients 
with heart involvement caused by EGPA the 
mortality rate was estimated as up to 50%. Early 
immunosuppressive treatment of patient with 
life-threating heart disease in EGPA can allow for 
the restoration of heart function and reduction of 
the mortality rate.
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